The FDA Can Regulate the Drug. But Can It Evaluate the Therapy? | Heidi Allen | TEDMED Spark

As psychedelic treatments move closer to clinical approval, the question is no longer just whether the drug works.

It is whether the therapy surrounding it can survive the approval process.

In this TEDMED Conversation, Heidi Allen explains how companies are reshaping psychedelic care into a model the FDA can more easily evaluate, potentially pushing therapy itself to the margins.

Full episode available on TEDMED.com July 13.

#tedmed #psychedelictherapy #mentalhealth #fda #healthcareinnovation